Research progress of exemption from radiotherapy after breast-conserving surgery in patients with early-stage breast cancer

doi:10.3760/cma.j.issn.1007-1245.2024.03.002

Abstract

Abstract:

Radiotherapy after breast-conserving surgery for patients with breast cancer is the standard treatment modality for early-stage breast cancer. Due to advances in imaging, surgery, and molecular pathology, downgrading of radiotherapy or even reasonable exemption from radiotherapy can be performed in low-risk patients with breast cancer to minimize the adverse effects of radiotherapy. This article reviews the evolutionary process of radiotherapy downgrading in breast cancer and the role of relevant pathological tests and genetic tests in assessing the prognosis of patients with breast cancer in radiotherapy, and discusses relevant trials on patients with hormone receptor-positive breast cancer combining multiple molecular tests for exemption from radiotherapy to identify patient groups that can be safely exempted from radiotherapy after breast-conserving surgery using available tumor biology and molecular predictions.

Key words:

Breast cancer, Breast-conserving surgery, Radiation de-escalation, Molecular diagnostic techniques, Prognosis, Progress

摘要：

乳腺癌患者保乳手术后行放疗是早期乳腺癌的标准治疗模式。由于影像学、手术、分子病理学的进步，乳腺癌患者中低风险人群可以进行放射治疗的降级，甚至合理地免除放疗来减少不良反应。本文综述了乳腺癌放疗降级的一个演变过程，回顾相关病理检测及基因检测在乳腺癌放疗中对其预后的评估作用，并讨论激素受体阳性乳腺癌患者结合多种分子检测进行免除放疗的相关试验，利用现有的肿瘤生物学和分子检测精准确定保乳术后可以安全免除放疗的患者群体。

关键词:

乳腺癌, 保乳术后, 放疗降级, 分子检测, 预后, 进展

Liu Ming, Liu Shuai, Zhang Nan.

Research progress of exemption from radiotherapy after breast-conserving surgery in patients with early-stage breast cancer [J]. International Medicine and Health Guidance News, 2024, 30(3): 357-362.

刘茗刘帅张楠.

早期乳腺癌患者保乳术后免除放疗的研究进展 [J]. 国际医药卫生导报, 2024, 30(3): 357-362.

References

[1] Early Breast Cancer Trialists' Collaborative G, Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials [J]. Lancet, 2011, 378(9804): 1707-1716. DOI:10.1016/S0140-6736(11)61629-2
[2] Abe O, Abe R, Enomoto K, et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials [J]. Lancet, 2005, 365(9472): 1687-1717. DOI:10.1016/s0140-6736(05)66544-0
[3] 中国抗癌协会乳腺癌诊治指南与规范(2021年版) [J]. 中国癌症杂志, 2021, 31(10): 954-1040. DOI:10.19401/j.cnki.1007-3639.2021.10.013
[4] 方涌文, 方键蓝, 刘镖水, 等.模拟复位验证在乳腺癌患者调强放疗中应用价值的探讨 [J].国际医药卫生导报, 2022,28(11):1482-1485. DOI:10.3760/cma.j.issn.1007-1245. 2022.11.001.
[5] Deshmukh AA, Shirvani SM, Lal L, et al. Cost-effectiveness analysis comparing conventional, hypofractionated, and intraoperative radiotherapy for early-stage breast cancer [J]. J Natl Cancer Inst, 2017, 109(11). DOI:10.1093/jnci/djx068
[6] 曹茜, 王义海, 韩有溪, 等.早期乳腺癌保乳术后大分割调强放疗与常规放疗的临床疗效比较 [J].临床肿瘤学杂志, 2018,23(2):150-154.
[7] Weng JK, Lei X, Schlembach P, et al. Five-year longitudinal analysis of patient-reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated whole-breast irradiation [J]. Int J Radiat Oncol Biol Phys, 2021, 111(2): 360-370. DOI:10.1016/j.ijrobp.2021.05.004
[8] Offersen BV, Alsner J, Nielsen HM, et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial [J]. J Clin Oncol, 2020, 38(31): 3615-3625. DOI:10.1200/JCO.20.01363
[9] Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials [J]. Lancet Oncol, 2013, 14(11): 1086-1094. DOI:10.1016/S1470-2045(13)70386-3
[10] Meattini I, Becherini C, Boersma L, et al. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer [J]. Lancet Oncol, 2022, 23(1): e21-e31. DOI:10.1016/S1470-2045(21)00539-8
[11] Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial [J]. Lancet, 2020, 395(10237): 1613-1626. DOI:10.1016/S0140-6736(20)30932-6
[12] Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial [J]. Lancet, 2019, 394(10215): 2165-2172. DOI:10.1016/S0140-6736(19)32515-2
[13] Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO) [J]. Int J Radiat Oncol Biol Phys, 2009, 74(4): 987-1001. DOI:10.1016/j.ijrobp.2009.02.031
[14] Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial [J]. Lancet, 2019, 394(10215): 2155-2164. DOI:10.1016/S0140-6736(19)32514-0
[15] Meattini I, Marrazzo L, Saieva C, et al. Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial [J]. J Clin Oncol, 2020, 38(35): 4175-4183. DOI:10.1200/JCO.20.00650
[16] 蓝辉银, 莫淼.近距离加速部分乳房照射对比全乳照射在早期乳腺癌患者保乳术后放疗中的疗效差异:GEC-ESTRO APBI研究10年随访结果解读 [J].肿瘤学杂志, 2023,29(3):255-261. DOI:10.11735/j.issn.1671- 170X. 2023.03.B015.
[17] Vaidya JS, Bulsara M, Baum M, et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial [J]. BMJ, 2020, 370: m2836. DOI:10.1136/bmj.m2836
[18] Kurtz J, Party EW. The curative role of radiotherapy in the treatment of operable breast cancer [J]. Eur J Cancer, 2002, 38(15): 1961-1974. DOI:10.1016/s0959-8049(02)00314-3
[19] Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials [J]. Lancet, 2005, 366(9503): 2087-2106. DOI:10.1016/S0140-6736(05)67887-7
[20] Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer [J]. N Engl J Med, 2004, 351(10): 963-970. DOI:10.1056/NEJMoa040595
[21] Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343 [J]. J Clin Oncol, 2013, 31(19): 2382-2387. DOI:10.1200/JCO.2012.45.2615
[22] Kunkler IH, Williams LJ, Jack WJ, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial [J]. Lancet Oncol, 2015, 16(3): 266-273. DOI:10.1016/S1470-2045(14)71221-5
[23] Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J]. Ann Oncol, 2011, 22(8): 1736-1747. DOI:10.1093/annonc/mdr304
[24] Park S, Koo JS, Kim MS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry [J]. Breast, 2012, 21(1): 50-57. DOI:10.1016/j.breast.2011.07.008
[25] Sestak I, Buus R, Cuzick J, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor–positive breast cancer [J]. JAMA Oncology, 2018, 4(4): 545-553. DOI:10.1001/jamaoncol.2017.5524
[26] Tseng YD, Uno H, Hughes ME, et al. Biological subtype predicts risk of locoregional recurrence after mastectomy and impact of postmastectomy radiation in a large national database [J]. Int J Radiat Oncol Biol Phys, 2015, 93(3): 622-630. DOI:10.1016/j.ijrobp.2015.07.006
[27] Liu FF, Shi W, Done SJ, et al. Identification of a low-risk Luminal A breast cancer cohort that may not benefit from breast radiotherapy [J]. J Clin Oncol, 2015, 33(18): 2035-2040. DOI:10.1200/JCO.2014.57.7999
[28] Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer [J]. J Clin Oncol, 2011, 29(32): 4273-4278. DOI:10.1200/jco.2010.31.2835
[29] Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer [J]. N Engl J Med, 2004, 351(27): 2817-2826. DOI:10.1056/NEJMoa041588
[30] Ontario Clinical Oncology Group (OCOG). A prospective cohort study evaluating risk of local recurrence fol lowing breast conserving surgery and endocrine therapy in low risk luminal a breast cancer (LUMINA)[DB/OL]. Washington, D.C.: Clinicaltrials. Gov. Published 2013. Accessed August 28, 2021. https://clinicaltrials. gov/ct2/show/study/NCT0179182
[31] University of Michigan Rogel Cancer Center. The IDEA study (individualized decisions for endocrine therapy alone) [DB/OL]. Washington, D.C.: Clinicaltrials.Gov. Published 2015. Accessed August 28, 2021. https://clinicaltrials.gov/show/NCT02400190
[32] Kirwan CC, Coles CE, Bliss J, et al. It's PRIMETIME. postoperative avoidance of radiotherapy: biomarker selection of women at very low risk of local recurrence [J]. Clin Oncol, 2016, 28(9): 594-596. DOI:10.1016/j.clon.2016.06.007
[33] Jian Zhang,MD, Fudan University. Examining personalised radiation therapy for low-risk early breast cancer (EXPERT) [DB/OL]. Washington, D.C.: Clinicaltrials.Gov. Published 2016. Accessed August 28, 2021. https://clinicaltrials.gov/ct2/show/ NCT02889874
[34] NRG Oncology. De-escalation of breast radiation trial for hormone sensitive: her-2 negative, oncotype recurrence score less than or equal to 18 breast cancer (DEBRA) [DB/OL]. Washington, D.C.: Clinicaltrials.Gov. Published 2021. Accessed August 28, 2021. https://clinicaltrials.gov/ ct2/show/NCT04852887
[35] Williams LJ, Kunkler IH, King CC, et al. A randomised controlled trial of post-operative radiotherapy following breast-conserving surgery in a minimum-risk population. Quality of life at 5 years in the PRIME trial [J]. Health Technol Assess, 2011, 15(12): 1-+. DOI:10.3310/hta15120
[36] Murphy CC, Bartholomew LK, Carpentier MY, et al. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review [J]. Breast Cancer Res Treat, 2012, 134(2): 459-478. DOI:10.1007/s10549-012-2114-5
[37] Blamey RW, Bates T, Chetty U, et al. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial [J]. Eur J Cancer, 2013, 49(10): 2294-2302. DOI:10.1016/j.ejca.2013.02.031
[38] Goldberg M, Sutradhar R, Paszat L, et al. Patterns of adjuvant care and outcomes of elderly women with stage I breast cancer after breast-conserving surgery: a population-based analysis [J]. Breast Cancer Res Treat, 2019, 176(3): 657-667. DOI:10.1007/s10549-019- 05266-0
[39] Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less [J]. J Clin Oncol, 2002, 20(20): 4141-4149. DOI:10.1200/JCO.2002.11.101
[40] Killander F, Anderson H, Kjellén E, et al. Increased cardio and cerebrovascular mortality in breast cancer patients treated with postmastectomy radiotherapy – 25 year follow-up of a randomised trial from the South Sweden Breast Cancer Group [J]. Eur J Cancer, 2014, 50(13): 2201-2210. DOI:10.1016/j.ejca.2014.04.033